Results 81 to 90 of about 25,891 (205)

Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood.
Johanna Braegelmann   +6 more
wiley   +1 more source

Refractory Thrombocytopenia Responds to Octreotide Treatment in a Case of Evans Syndrome with Gastric Neuroendocrine Tumor

open access: yesCase Reports in Hematology, 2013
A 37-year-old woman with history of Evans Syndrome with poor response to high-dose corticoid treatment presented to the emergency department with gastrointestinal and vaginal bleeding.
Kocfa Chung-Delgado   +4 more
doaj   +1 more source

18F-AlF-NOTA-octreotide PET/CT and 3D printing technology for precision diagnosis and treatment of phosphaturic mesenchymal tumors in patients with tumor-induced osteomalacia: two case reports

open access: yesFrontiers in Endocrinology
ObjectiveThis study aims to report the application of 18F-AlF-NOTA-Octreotide PET/CT and 3D printing technology in the diagnosis and treatment of phosphaturic mesenchymal tumors (PMT) in patients with tumor-induced osteomalacia (TIO).Case presentationA ...
Gang Zhao   +10 more
doaj   +1 more source

A Preliminary Exploratory Study on the Application of Gd‐EOB‐DTPA‐Enhanced MRI for Assessing Gallbladder Ejection Fraction in Cholecystolithiasis Patients

open access: yesCanadian Journal of Gastroenterology and Hepatology, Volume 2026, Issue 1, 2026.
Objective To preliminarily explore the feasibility and clinical implications of using gadoxetic acid disodium (Gd‐EOB‐DTPA)‐enhanced magnetic resonance imaging (MRI) for assessing the gallbladder ejection fraction (GBEF) in patients with cholecystolithiasis.
Ruikun Zhang   +14 more
wiley   +1 more source

Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice

open access: yesHeliyon
Background: Patients with high-risk neuroblastoma (NB) have a 5-year event-free survival of less than 50 %, and novel and improved treatment options are needed. Radiolabeled somatostatin analogs (SSTAs) could be a treatment option.
A. Romiani   +12 more
doaj   +1 more source

Differential Effects of Somatostatin on TNF Receptors and Apoptosis in Hepatocellular Carcinoma Cell Lines

open access: yesGastroenterology Insights
The anti-tumoral activity of somatostatin has been demonstrated in both animal experiments and human tumors. Clinical trials have reported conflicting results.
Maria Georgiadou   +6 more
doaj   +1 more source

An Unusual Case of Resistant Hepatic Hydrothorax Treated with Octreotide Infusion

open access: diamond, 2020
Mehrdad Ghahremani‐Ghajar   +3 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy